Abselion has expanded its Amperia™ platform with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit. Both ready-to-use kits incorporate Thermo Fisher Scientific’s CaptureSelect™ affinity reagents, delivering high specificity, consistency, and broad serotype coverage.
Designed for rapid, reliable quantification of adeno-associated virus (AAV) capsids, the kits streamline workflows by reducing the need for in-house optimisation. Researchers can generate reproducible titre measurements across a wide range of serotypes and sample conditions, from purified to complex matrices.
With these additions, Abselion strengthens its support for gene therapy research and development, offering scientists a dependable solution for total capsid quantification on the compact Amperia platform.
For more details, visit abselion.com/assay-kits
